



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at [ScienceDirect](#)

Life Sciences

journal homepage: [www.elsevier.com/locate/lifescie](http://www.elsevier.com/locate/lifescie)



## Corrigendum

# Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]



Abdo A. Elfiky

*Biophysics Department, Faculty of Sciences, Cairo University, Giza, Egypt*

The author regrets that the article omitted to clarify that parts of Sections 2.1, 2.2, 3.1 and 3.2, as well as of Figs. 1 and 2 were reused from the article that was previously published by the author in Life

Sciences 248 (2020) 117477 <https://doi.org/10.1016/j.lfs.2020.117477>.

The author would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.lfs.2020.117592>

E-mail addresses: [abdo@sci.cu.edu.eg](mailto:abdo@sci.cu.edu.eg), [aelfiky@ictp.it](mailto:aelfiky@ictp.it).

<https://doi.org/10.1016/j.lfs.2020.118350>

Available online 28 August 2020

0024-3205/ © 2020 Elsevier Inc. All rights reserved.